About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Global Antibiotics Market Size, CAGR of 4.1%, Top Share and Forecast to 2031
Antibiotics Market

Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, Other), By Spectrum of Activity (Broad-spectrum Antibiotic, Narrow-spectrum Antibiotic) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI906DR
Last Updated : November 20, 2024
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Antibiotics Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Cephalosporin
        1. By Value
      3. Penicillin
        1. By Value
      4. Fluoroquinolone
        1. By Value
      5. Macrolides
        1. By Value
      6. Carbapenem
        1. By Value
      7. Aminoglycosides
        1. By Value
      8. Sulfonamides
        1. By Value
      9. Other
        1. By Value
    3. By Spectrum of Activity
      1. Introduction
        1. Spectrum of Activity By Value
      2. Broad-spectrum Antibiotic
        1. By Value
      3. Narrow-spectrum Antibiotic
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Cephalosporin
        1. By Value
      3. Penicillin
        1. By Value
      4. Fluoroquinolone
        1. By Value
      5. Macrolides
        1. By Value
      6. Carbapenem
        1. By Value
      7. Aminoglycosides
        1. By Value
      8. Sulfonamides
        1. By Value
      9. Other
        1. By Value
    3. By Spectrum of Activity
      1. Introduction
        1. Spectrum of Activity By Value
      2. Broad-spectrum Antibiotic
        1. By Value
      3. Narrow-spectrum Antibiotic
        1. By Value
    4. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Cephalosporin
          1. By Value
        3. Penicillin
          1. By Value
        4. Fluoroquinolone
          1. By Value
        5. Macrolides
          1. By Value
        6. Carbapenem
          1. By Value
        7. Aminoglycosides
          1. By Value
        8. Sulfonamides
          1. By Value
        9. Other
          1. By Value
      2. By Spectrum of Activity
        1. Introduction
          1. Spectrum of Activity By Value
        2. Broad-spectrum Antibiotic
          1. By Value
        3. Narrow-spectrum Antibiotic
          1. By Value
    5. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Cephalosporin
        1. By Value
      3. Penicillin
        1. By Value
      4. Fluoroquinolone
        1. By Value
      5. Macrolides
        1. By Value
      6. Carbapenem
        1. By Value
      7. Aminoglycosides
        1. By Value
      8. Sulfonamides
        1. By Value
      9. Other
        1. By Value
    3. By Spectrum of Activity
      1. Introduction
        1. Spectrum of Activity By Value
      2. Broad-spectrum Antibiotic
        1. By Value
      3. Narrow-spectrum Antibiotic
        1. By Value
    4. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Cephalosporin
          1. By Value
        3. Penicillin
          1. By Value
        4. Fluoroquinolone
          1. By Value
        5. Macrolides
          1. By Value
        6. Carbapenem
          1. By Value
        7. Aminoglycosides
          1. By Value
        8. Sulfonamides
          1. By Value
        9. Other
          1. By Value
      2. By Spectrum of Activity
        1. Introduction
          1. Spectrum of Activity By Value
        2. Broad-spectrum Antibiotic
          1. By Value
        3. Narrow-spectrum Antibiotic
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Cephalosporin
        1. By Value
      3. Penicillin
        1. By Value
      4. Fluoroquinolone
        1. By Value
      5. Macrolides
        1. By Value
      6. Carbapenem
        1. By Value
      7. Aminoglycosides
        1. By Value
      8. Sulfonamides
        1. By Value
      9. Other
        1. By Value
    3. By Spectrum of Activity
      1. Introduction
        1. Spectrum of Activity By Value
      2. Broad-spectrum Antibiotic
        1. By Value
      3. Narrow-spectrum Antibiotic
        1. By Value
    4. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Cephalosporin
          1. By Value
        3. Penicillin
          1. By Value
        4. Fluoroquinolone
          1. By Value
        5. Macrolides
          1. By Value
        6. Carbapenem
          1. By Value
        7. Aminoglycosides
          1. By Value
        8. Sulfonamides
          1. By Value
        9. Other
          1. By Value
      2. By Spectrum of Activity
        1. Introduction
          1. Spectrum of Activity By Value
        2. Broad-spectrum Antibiotic
          1. By Value
        3. Narrow-spectrum Antibiotic
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Cephalosporin
        1. By Value
      3. Penicillin
        1. By Value
      4. Fluoroquinolone
        1. By Value
      5. Macrolides
        1. By Value
      6. Carbapenem
        1. By Value
      7. Aminoglycosides
        1. By Value
      8. Sulfonamides
        1. By Value
      9. Other
        1. By Value
    3. By Spectrum of Activity
      1. Introduction
        1. Spectrum of Activity By Value
      2. Broad-spectrum Antibiotic
        1. By Value
      3. Narrow-spectrum Antibiotic
        1. By Value
    4. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Cephalosporin
          1. By Value
        3. Penicillin
          1. By Value
        4. Fluoroquinolone
          1. By Value
        5. Macrolides
          1. By Value
        6. Carbapenem
          1. By Value
        7. Aminoglycosides
          1. By Value
        8. Sulfonamides
          1. By Value
        9. Other
          1. By Value
      2. By Spectrum of Activity
        1. Introduction
          1. Spectrum of Activity By Value
        2. Broad-spectrum Antibiotic
          1. By Value
        3. Narrow-spectrum Antibiotic
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Cephalosporin
        1. By Value
      3. Penicillin
        1. By Value
      4. Fluoroquinolone
        1. By Value
      5. Macrolides
        1. By Value
      6. Carbapenem
        1. By Value
      7. Aminoglycosides
        1. By Value
      8. Sulfonamides
        1. By Value
      9. Other
        1. By Value
    3. By Spectrum of Activity
      1. Introduction
        1. Spectrum of Activity By Value
      2. Broad-spectrum Antibiotic
        1. By Value
      3. Narrow-spectrum Antibiotic
        1. By Value
    4. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Cephalosporin
          1. By Value
        3. Penicillin
          1. By Value
        4. Fluoroquinolone
          1. By Value
        5. Macrolides
          1. By Value
        6. Carbapenem
          1. By Value
        7. Aminoglycosides
          1. By Value
        8. Sulfonamides
          1. By Value
        9. Other
          1. By Value
      2. By Spectrum of Activity
        1. Introduction
          1. Spectrum of Activity By Value
        2. Broad-spectrum Antibiotic
          1. By Value
        3. Narrow-spectrum Antibiotic
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Antibiotics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Allergan
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Novartis
    3. Mylan N.V
    4. Sanofi
    5. Bayer
    6. Zydus Cadila
    7. Bausch Health
    8. Teva Pharmaceutical Industries Ltd.
    9. Melinta Therapeutics
    10. Lupin
    11. Amneal Pharmaceuticals LLC
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Global Antitumor Antibiotics Market Insights The global antitumor antibiotics market size was valued at USD 4,271.71 million in 2024 and is projected to grow from USD 4,533.43 million in 2025 to reach USD 6,627.14 million by 2033, exhibiting a
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.